Hoping to raise awareness of this relatively new discovery among MS patients is Sanofi, which has sold Aubagio for relapsing-remitting MS for over a decade and has multiple other treatments for ...

Also Read: FDA Approves Regeneron/Sanofi’s Blockbuster Dupixent For Smoker’s Lung Disease. The FDA approved the drug in 2022. Administered as chronic IV treatment. Enjaymo generated ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate tolebrutinib, linking the BTK inhibitor to a 31% delay in time to onset of ...

Sanofi is following in the footsteps of a number of its peers in pharma with a plan to spin off its consumer health business into a separate company and focus its efforts on its prescription drugs ...

Following the FDA's green light for a combo regimen of Sanofi’s Sarclisa in patients with newly diagnosed multiple myeloma last week, J&J has wasted little time hitting back with new data on its ...

Sanofi Healthcare Bidders Revising Offers Over Talc Concerns CD&R, PAI look to exclude aspects of Gold Bond unit in bids Consumer business could be valued at €15 billion in a sale ...

NEW YORK, Sept 23 (Reuters) - Sanofi's (SASY.PA), opens new tab chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a variety of new ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

Regeneron REGN-2.47%decrease; red down pointing triangle Pharmaceuticals and Sanofi SAN-1.92%decrease; red down pointing triangle have won U.S. Food and Drug Administration expanded approval of ...

(Reuters) -Sanofi has received two separate bids from private equity firms for its consumer health unit, which could be valued at 15 billion euros ($16.74 billion) or more, Bloomberg News reported ...